中基長壽科學(00767.HK)折讓34%配股 淨籌3,044萬元
中基長壽科學(00767.HK)宣布,於6月15日與認購人訂立協議,配發近9,285.6萬股新股,相當於經擴大後已發行股本約14.52%,每股價格為0.33元,較該股份上個交易日(13日)收市價0.5元折讓34%。
是次將籌集將83,064.24萬元,所得淨額預料為約3,044.24萬元,當中約36.3%將用於香港中心的現有的長壽科學業務,約13.2%將用於營運深圳長壽科學銷售渠道,約17.5%將分配用於收回借貸及金融諮詢業務下策略夥伴已抵押房屋貸款涉及的法律專業費用及相關服務成本,餘下33%為集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.